Login to Your Account



TRIALS TO START IN 2017

Advaxis, Amgen strike $540M preclinical-stage immunotherapy alliance; $40M cash up front

By Michael Fitzhugh
Staff Writer

Wednesday, August 3, 2016

Global rights to Advaxis Inc.’s preclinical cancer immunotherapy, ADXS-NEO, are going to Amgen Inc. for a combined pledge of up to $540 million, giving Advaxis new cash to fuel its FDA fast-tracked phase III cervical cancer treatment, AXAL, while feeding Amgen’s ongoing interest in cancer vaccines, a pursuit that led to approval of the first FDA-approved oncolytic virus therapy, Imlygic (talimogene laherparepvec), last October.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription